In Canada

In the USA

Linkedin

In Canada

In the USA

Linkedin

Empowering Renal Health

Welcome to the world dedicated to the development of biologics for the treatment of metabolic diseases.

Founded in 2023:

EPOK Therapeutics is dedicated to advancing biologic therapies for metabolic diseases, leveraging over two decades of expertise in antibody engineering and preclinical research.

Scientific Approach:

We specialize in the development of engineered agonist and antagonist antibodies with a focus on reducing off-target activity, enhancing safety profiles, and optimizing dosing regimens and production efficiency.

Scientific Approach:

We specialize in the development of engineered agonist and antagonist antibodies with a focus on reducing off-target activity, enhancing safety profiles, and optimizing dosing regimens and production efficiency.

Research Focus:

Our research is centered on addressing anemia and phosphate imbalances, particularly in the context of chronic kidney disease (CKD) and a range of genetic and acquired disorders.

Advancing Research in Anemia and Phosphate Wasting Disorders

EPOK Therapeutics is focused on developing targeted therapies for anemia and phosphate wasting disorders, aiming to improve safety and therapeutic efficacy through ongoing scientific innovation.

Phosphate Wasting Disorder:

KLOT-1123 is a next-generation antibody
designed to selectively target FGF23,
providing a safer and more effective
treatment for phosphate-related disorders
like hypophosphatemic rickets and CKD…. Read more

Anemia Treatment Innovation:

EPRA-0322 offers a new approach to treating
chronic anemia with low-dose, infrequent
administration, and a focus on improved
safety for patients with CKD and cancer… Read more